Schizophrenia is a neuropsychiatric disease affecting 20 million people globally. Patients present with a wide variety of symptoms and severities. Most patients are treated with standard antipsychotic drugs, but given the disease’s heterogeneity, it’s not surprising that as many as 30% of patients are classified as treatment-resistant.
We clustered a schizophrenia population dataset to identify five different patient communities. These contain distinct combinations of genes with shared biological mechanisms, providing further insights into their role in underlying disease pathology and patient phenotype.
Of the 85 significant genes we identified, most have not previously been implicated in the disease. They nonetheless have strong mechanistic links to several pathways associated with schizophrenia pathogenesis, including altered neurotransmission, inflammation, and regulation of neuronal development and synaptic plasticity.